1. Winkler DG, Faia KL, DiNitto JP, et al. PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013;20(11):1364–74.
2. Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase delta/gamma inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017;26(5):625–32.
3. US FDA. Duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); 2018. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm621503.htm . Accessed 10 Oct 2018.
4. Verastem Inc. Copiktra (duvelisib), capsules for oral use: US prescribing information; 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf . Accessed 10 Oct 2018.
5. Infinity Pharmaceuticals Inc. Infinity and Intellikine enter agreement to develop oral therapies targeting PI3 kinase delta, gamma [media release]; 8 Jul 2010. http://globenewswire.com/news-release/2010/07/08/424597/195928/en/Infinity-and-Intellikine-Enter-Agreement-to-Develop-Oral-Therapies-Targeting-PI3-Kinase-Delta-Gamma .